Janux Therapeutics, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Janux Therapeutics, Inc. (JANX) had Operating Lease, Weighted Average Discount Rate, Percent of 8.00% as of 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2022-11-10
- 2022-09-30: Operating Lease, Weighted Average Discount Rate, Percent 8.00%.
- 2022-06-30: Operating Lease, Weighted Average Discount Rate, Percent 8.00%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2022-09-30 | 8.00% 10-Q · filed 2022-11-10 |
| 2022-06-30 | 8.00% 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |